Tagged with

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

USA With Rare Disease Day coming up on February 28th, one of the leading organizations dedicated to serving affected patients in the US, the National Organization for Rare Disorders (NORD), is making a push to put the spotlight on the limited access to diagnosis, treatment and care suffered by rare disease…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare   STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Singapore Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the region, his changing priorities during these challenging times, and the importance of building a unified culture across the regional organization,…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent acquisition of DIFICLIR™ from Astellas, and the company’s recognition as a Great Place to Work® (GPTW) in Switzerland.   For…

Global Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19 vaccines from bench to market in less than a year and introduces the IFPMA’s new #TeamVaccines campaign, shedding light on the personal stories behind this miraculous effort.   The story of COVID-19…

Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of…

Singapore MSD’s Ashish Pal describes how he led the Singapore, Malaysia, and Brunei cluster through a challenging 2020; the importance of leveraging learnings from the past year to create a more resilient, agile, and digitally-focused affiliate; and why increased levels of public-private collaboration in the region are vital to building a…

Global One of the more intriguing aspects about the new wave of cell and gene therapies (CGT) coming onstream is that they are not just technologically innovative in terms of the sheer novelty of the medical science, but they are also serving to upend the traditional operating model of the pharma…